CVS Caremark is adding Zepbound, Eli Lilly’s obesity drug, back to its commercial insurance plan formularies, more than a year after it stopped covering it in favor of Novo Nordisk’s Wegovy.

Florida's Attorney General has opened an investigation into CVS Health's (NYSE:CVS) Caremark pharmacy benefit manager for ...

In a reversal from last year, CVS will begin covering Eli Lilly's Zepbound and Foundayo in its standard prescription plan, a win for GLP-1 patients.

Add Yahoo as a preferred source to see more of our stories on Google. When Zepbound, Eli Lilly's highly anticipated weight loss drug, hit the market a year and a half ago, it marked a turning point ...

CVS Caremark will resume covering the weight loss drug Zepbound this year after it removed it from its list of covered medications last year, drugmaker Eli Lilly said.

(CNN) — Last week, Tara Eacobacci had an appointment with her doctor that was devoted exclusively to the topic of health insurance. A major change to her prescription benefits meant the medication she ...

Plaintiffs are going to court to challenge CVS Caremark’s decision to stop covering Zepbound, a weight-loss drug that is also used to treat sleep apnea. Plaintiff Martin Hamburger filed his lawsuit in ...

AM Best has assigned a Financial Strength Rating of A (Excellent) and a Long-Term Issuer Credit Rating of “a” (Excellent) to CVS Caremark Indemnity Ltd. (CVS Caremark Indemnity) (Bermuda). The outlook ...

-- Contract to support 9.7 million Aetna PBM members representing approximately $9.5 billion in annual drug spend -- HARTFORD, Conn. & WOONSOCKET, R.I.--(BUSINESS WIRE)-- Aetna (NYSE: AET) and CVS ...